STOCKSCREENR

0UNL.L

LSE

Nektar Therapeutics

$85.11+2.13(+2.57%)Mkt Cap: $1.73B

Key Stats

Market Cap

$1.73B

P/E Ratio

-31.95

EPS

$-2.66

Dividend Yield

0.00%

52-Week Range

$82.00 — $85.58

Volume

1.07K

Avg Volume

4.37K

Beta

1.18

Price Alerts for 0UNL.L

Get alerted when 0UNL.L hits your target price.

$

Free — enter your email to get started

Valuation

P/E (TTM)

-31.95

Forward P/E

—

PEG Ratio

0.36

P/S (TTM)

31.18

P/B (TTM)

19.17

P/FCF

—

EV/EBITDA

—

EV/Sales

—

Financial Health

ROE (TTM)

-3.99%

ROA (TTM)

-0.59%

ROIC

—

Gross Margin

1.00%

Operating Margin

-2.38%

Net Margin

—

Debt/Equity

1.66

Current Ratio

4.97

Growth

EPS Growth (YoY)

—

Revenue Growth (YoY)

—

EPS Growth (3Y)

+0.39%

EPS Growth (5Y)

+0.21%

Sales Growth (3Y)

-0.01%

Sales Growth (5Y)

-0.00%

EPS Est (This Year)

$-9.87

EPS Est (Next Year)

$-11.53

Dividends

Dividend Yield

—

Annual Dividend

—

Payout Ratio

—

Frequency

—

Ex-Dividend Date

—

Cash/Share

$12.11

Ownership

Institutional %

—

Inst. Net Change

—

Insider Net Shares (90d)

-603

Outstanding Shares

20.34M

Float

18.89M

Free Float %

92.85%

About

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Country

US

Exchange

LSE

IPO Date

2018-07-18

Employees

61

CEO

Howard W. Robin

Index Membership

—

Website

https://www.nektar.com

Nektar Therapeutics (0UNL.L) is a healthcare company in the medical - pharmaceuticals industry listed on the LSE. With a market capitalization of $1.73B, a P/E ratio of -31.95, 0UNL.L is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare 0UNL.L against other stocks using dozens of fundamental and technical filters.

Similar Stocks

0RU5.L

Oncoinvent ASA

$49.50

+3.13%

$1.94B

ATAI

Atai Beckley N.V

$4.16

+0.97%

$784.68M

0J2O.L

Halozyme Therapeutics, Inc.

$64.11

+1.60%

$7.57B

0RA9.L

Abivax S.A.

$92.20

-0.59%

$7.30B

0QND.L

Bachem Holding AG

$70.06

+2.29%

$5.24B

0L35.L

Sarepta Therapeutics, Inc.

$21.09

+2.59%

$2.11B

Frequently Asked Questions

What is Nektar Therapeutics's P/E ratio?

Nektar Therapeutics (0UNL.L) has a trailing twelve-month (TTM) P/E ratio of -31.95. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does Nektar Therapeutics pay a dividend?

No, Nektar Therapeutics (0UNL.L) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is Nektar Therapeutics's market cap?

Nektar Therapeutics (0UNL.L) has a market capitalization of $1.73 billion, classifying it as a small-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.